Jazz Pharmaceuticals (JAZZ) Equity Average (2011 - 2026)

Jazz Pharmaceuticals' Equity Average history runs 16 years deep, the most recent figure standing at $4.4 billion for Q1 2026.

• In Q1 2026, Equity Average rose 7.04% year-over-year to $4.4 billion; the TTM figure through Mar 2026 stood at $4.4 billion (up 7.04% YoY), while the FY2025 annual figure was $4.2 billion, up 7.43% from the prior year.
• Equity Average was $4.4 billion for Q1 2026 at Jazz Pharmaceuticals, up from $4.1 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $4.4 billion in Q1 2026 to a low of $2.9 billion in Q4 2022.
• Historically, Equity Average has averaged $3.7 billion across 5 years, with a median of $3.7 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Equity Average retreated 26.32% in 2022, then gained 23.93% in 2023.
• A 5-year view of Equity Average shows it stood at $2.9 billion in 2022, then increased by 23.93% to $3.6 billion in 2023, then climbed by 14.37% to $4.1 billion in 2024, then climbed by 0.16% to $4.1 billion in 2025, then gained by 6.93% to $4.4 billion in 2026.
• The last three Equity Average figures came in at $4.4 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.8 billion (Q3 2025), per Business Quant data.